Compare XPER & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | FENC |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | 1460 | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.7M | 266.4M |
| IPO Year | 2021 | 2010 |
| Metric | XPER | FENC |
|---|---|---|
| Price | $5.48 | $5.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 367.9K | 186.4K |
| Earning Date | 05-06-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,105,000.00 | $47,538,000.00 |
| Revenue This Year | $4.03 | $75.81 |
| Revenue Next Year | $8.11 | $25.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $5.07 | $4.68 |
| 52 Week High | $8.24 | $9.92 |
| Indicator | XPER | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 31.07 |
| Support Level | $5.07 | N/A |
| Resistance Level | $6.37 | $8.27 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 4.41 | 2.21 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.